PrTEPMETKOTM (Tepotinib tablets)


  • 225mg

Professed Standard Therapeutic Classification: Other Protein Kinase Inhibitors (L01EX21)

TEPMETKO has been issued marketing authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization.  For further information for TEPMETKO please refer to Health Canada’s Notice of Compliance with conditions - drug products web site

TEPMETKO is indicated for:

  • The treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.
Action SVG
Action SVG
Action SVG